<DOC>
	<DOCNO>NCT01334190</DOCNO>
	<brief_summary>This non-comparative prospective observational study woman use Zarin primary method contraception Kenya . It conduct close collaboration Kenya MoH several MoH-affiliated clinic experience implant sufficient expect flow implant user per month . The investigator enroll total 600 woman divide two cohort one-year prospective study : - prospective cohort consist 300 woman followed-up 3 12 month enrollment ; - surveillance cohort 300 woman report back clinic 12 month enrollment complication , medical problem , pregnancy , want remove implant The main study outcome pregnancy , immediate delay complication associate insertion removal , adverse event , early discontinuation reason discontinuation , level woman 's satisfaction Zarin service .</brief_summary>
	<brief_title>A Prospective Observational Study Performance Zarin Kenya</brief_title>
	<detailed_description>A non-comparative prospective observational study woman use Zarin primary method contraception Kenya . It conduct close collaboration Kenya MoH several MoH-affiliated clinic experience implant sufficient expect flow implant user per month . The investigator enroll total 600 woman divide two cohort one-year prospective study : - prospective cohort consist 300 woman followed-up 3 12 month enrollment ; - surveillance cohort 300 woman report back clinic 12 month enrollment complication , medical problem , pregnancy , want remove implant The main study outcome pregnancy , immediate delay complication associate insertion removal , adverse event , early discontinuation reason discontinuation , level woman 's satisfaction Zarin service .</detailed_description>
	<criteria>age 1844 year , inclusive willing sign inform consent document willing give contact information follow agree return followup visit decide receive Zarin method contraception meet clinic criterion eligibility method contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquire immunodeficiency syndrome</keyword>
	<keyword>ALT ( SGPT ) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST ( SGOT ) aspartate aminotransferase</keyword>
	<keyword>DCF data collection form</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA ( U.S. ) Food Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guideline</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference Harmonisation</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU international unit</keyword>
	<keyword>mg milligram ( )</keyword>
	<keyword>mm3 cubic millimeter ( )</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>Âµg microgram</keyword>
	<keyword>ULN upper limit normal range</keyword>
	<keyword>WB Western Blot</keyword>
	<keyword>post-marketing monitoring</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>acceptability</keyword>
</DOC>